Amyotrophic Lateral Sclerosis clinical trials

View All

evolving-als-treatment-landscape
How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape?

Mitsubishi replacing RADICAVA’s Intravenous (IV) formulation with Oral. Opinion on Amylyx Pharma’s recent approval, RELYVRIO  The amyotrophic lateral sclerosis treatment landscape is stringent and includes multidisciplinary care, such as physical therapy, speech therapy, dietary counseling, heat or whirlpoo...

Find More

Radicava for ALS
Amyotrophic Lateral Sclerosis Treatment: The Journey of Radicava and Highlights of Riluzole Formulations

Amyotrophic Lateral Sclerosis (ALS) or Lou Gehrig’s disease is a rare, progressive, and fatal neuromuscular disease characterized by degeneration of upper and lower motor neurons. While it is associated with a mortality rate of 50% within 30 months of Amyotrophic Lateral Sclerosis symptoms onset, there is still no ...

Find More